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A B S T R A C T
We provide a review of current literature of native valve Candida tropicalis endocarditis.
A 41-year old man presented with C. tropicalis candidemia complicated by superior vena cava mass and
right main pulmonary artery thrombus. The patient achieved clinical and microbiologic cure with
AngioVac of the mass and echinocandin for six weeks. Long-term suppression was challenging given the
C. tropicalis strain was resistant to fluconazole, voriconazole and posaconazole. Additional susceptibilities
were obtained and he remained relapse-free at 12 months with isavuconazole.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Candida infective endocarditis (IE) is the most common form of
fungal endocarditis (50 %) but accounts for only 2 % of all IE cases.
Candida IE is seen in about 15 % of all candidemia cases. Candida
albicans (44 %) is the causative species in most of the cases. Other
common species include C. parapsilosis (27 %), C. tropicalis (10 %)
and C. glabrata (6 %). Risk factors for Candida IE include history of
prosthetic valve, cardiac implantable devices (pacemaker, defibril-
lator, left ventricular assist device), injection drug use, bacterial IE,
chemotherapy, prolonged presence of central venous catheters,
and renal replacement therapy. Clinical presentation is similar to
bacterial IE but emboli to the large vessels are more frequent [1].
The incidence of Candida IE in renal replacement patients is
2.5 %. Incidence is higher in patients receiving hemodialysis (HD)
compared to peritoneal dialysis. The risk is two fold higher in HD
recipients with central venous catheters (CVC) compared with
those with arteriovenous fistulas. In-patient mortality of CVC
associated Candida IE is 22 % and 55 % at one year [2].
Since medical therapy alone has occasionally been curative,
combination of antifungals and valve replacement are considered
the cornerstone of treatment for Candida IE. Valve repair and
vegetectomy are alternatives to the valve replacement. Currently,
the need for surgery in all patients is being questioned as recent* Corresponding author at: Indiana University School of Medicine, 550 N
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management alone may be similar to post valve replacement
surgery. However, pending new information, the recommenda-
tions per Infectious Diseases Society of America (IDSA) for Candida
IE include initial treatment with lipid formulation of amphotericin
B (with or without flucytosine) or high-dose echinocandin. Azoles
are not considered first line as they have decreased activity when
compared with echinocandins against biofilms formed by Candida
in vitro, and they penetrate poorly into vegetations. Long-term
suppression with azoles is recommended to prevent relapses if
valve surgery is not feasible [3].
Case
The patient, a 41-year old male with past medical history of
hypertension and end stage renal disease on hemodialysis (HD)
was transferred to our hospital for Candida tropicalis infective
endocarditis. Ten months prior to the admission, he was admitted
to an outside hospital with pulmonary septic emboli, respiratory
failure, and renal failure resulting in renal replacement therapy
with HD. A chest tunneled dialysis catheter and right arm
atriovenous fistula was placed. Two sets of blood cultures and
transesophageal echocardiogram (TEE) were negative. He was
treated empirically with intravenous meropenem for six weeks for
presumed endovascular infection. Six months prior to the
admission, he noticed black tar substance in his dialysis catheter.
The catheter was exchanged initially and subsequently removed a
month later. Two weeks prior to admission, patient experienced
intermittent fever, anorexia, nausea and vomiting. Blood culturesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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C. tropicalis. TEE showed a large mobile 2 cm superior vena cava
(SVC) mass attached to the right atrium and possible an aortic root
abscess (Fig. 1). The vegetation appeared to be attached to the
fibrous cast left from the previous dialysis catheter.
The patient was transferred to our facility for cardiovascular
surgery evaluation. On arrival, patient complained of fever, chills,
sweats, neck and back pain. He had no history of injection drug use,
immunosuppressive therapy and no indwelling hardware. His
vitals showed temperature 101.1 F, blood pressure 123/71, heart
rate 98/min, respiratory rate 18/min, and oxygen saturation 92 % at
room air. He appeared uncomfortable and had bilateral rales on
lung auscultation. A 3/6 systolic murmur was best heard in the left
sternal border, most prominent at 2nd and 5th intercostal space.
No spinal tenderness to palpation was appreciated. Chest CT
showed multiple bilateral septic emboli and large right main
pulmonary artery thrombus (Fig. 2). Patient was initially started on
intravenous (IV) amphotericin B but developed severe back pain so
antifungal was changed to IV micafungin 150 mg once a day.
Patient was evaluated by cardiovascular surgery but was not
considered a valve replacement candidate due to lack of valve
vegetation on cardiac CT scan. Ophthalmologic exam was negative
for endopthalmitis. CT scan of the abdomen and pelvis and MRI of
the vertebral spine showed no infection.
Repeat blood cultures were positive for C. tropicalis with
following mean inhibitory concentrations (MIC): micafungin 0.016
mg/L, fluconazole 256 mg/L, itraconazole 16 mg/L, voriconazole
8 mg/l and posaconazole 8 mg/L. Additional susceptibilities
were requested for isavuconazole. The patient underwent right
pulmonary thrombectomy. The thrombus culture was positive for
C. tropicalis. Interventional radiologist performed an AngioVac
procedure and removed 75 % of the SVC mass. While inpatient, IVFig. 1. Transesophageal Echocardiogram: Lmicafungin 150 mg once a day was continued and post AngioVac
blood cultures were negative. He improved clinically and refused
any indwelling catheter. On discharge from the hospital, IV
micafungin was switched to 200 mg on dialysis days to complete
6 weeks course. Post six weeks of IV micafungin, TEE showed
resolution of the cardiac mass. Isavuconazole MIC was 0.03 mg/l
and he was switched to oral isavuconazle for long-term suppres-
sion. At one-year follow-up, patient was clinically stable.
Methods
We conducted a Pubmed based search for Candida tropicalis
endocarditis, which yielded 47 results. Post application of ‘Adult:
age 19+’ filter, the results were narrowed to 26 articles. Case
reports with prosthetic valve (4) or cardiac device (4) or
polymicrobial infections (2) or different Candida species (2) or
basic science articles (2) were excluded. Twelve remaining case
reports of native valve C. tropicalis IE are summarized briefly in
Table 1 [4–15].
Discussion
We present a case of central venous catheter associated native
valve Candida tropicalis endocarditis successfully treated with
AngioVac of the vegetation along with intravenous echinocandin
for 6 weeks followed by oral isavuconazole for suppression. Only
two prior cases of native valve C. tropicalis achieved microbiologic
cure without valve replacement. Unfortunately on long-term
follow up, these two patient died (Table 1). We found four cases of
Candida endocarditis treated successfully with AngioVac proce-
dures. Jones et al. described a case of C. albicans cardioverter-
defibrilattor lead vegetation treated with AngioVac aspiration of aarge mobile superior vena cava mass.
Table 1








[4] Pancreatitis Tricuspid Yes
TVR
Amphotericin B + flucytosine x 2
weeks followed by flucytosine x 4
weeks followed by long term oral
fluconazole
Cured
[5] IDU, Burns, CVC Aortic, Mitral Yes
AVR, MVR
Micafungin x 3 weeks switched to




IV Fluconazole x 7 weeks Cured
[7] Aortic No Amphotericin B switched to
Caspofungin
Cured
Later died of refractory heart failure
[8] TURP/ Candiduria Aortic No Amphotericin B + flucytosine Failure: death prior to valve surgery
[9] TPN Tricuspid Yes
TVR
Amphotericin B + flucytosine Cured
[10] Aortic No IV Fluconazole x 7 weeks Cured







Amphotericin B + fluconazole
Cured
Stable at 10 month follow-up
[12] IHSS Mitral No Amphotericin B x 8 weeks Failure:
Died of
Pseudomonas bacteremia
[13] HL on chemotherapy No None Failed:
Autopsy diagnosis





Died 20 days pos-op





Aortic valve replacement-AVR; Cerebrovascular accident-CVA; Hodgkin’s Lymphoma (HL); Idiopathic Hypertrophic Subortic Stenosis-IHSS; Injection drug use-IDU; Mitral
valve replacement-MVR; Rheumatoid Arthritis-RA; Total parenteral nutrition-TPN; Transurethral resection of the prostate-TURP; TVR-Tricuspid valve replacement.
Fig. 2. Multiple pulmonary septic emboli and Right main pulmonary artery thrombus.
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Talebi et al, Tanaka et al, and Kalotericuset et al. each successfully
treated a fungal tricuspid valve vegetation with an AngioVac
procedure [17–19].
Per IDSA guidelines, clinically stable patients with susceptible
Candidaisolates who have cleared Candidafrom the bloodstream,
can be changed to oral fluconazole to complete the treatment.
Based on susceptibilities, other azole options could be voriconazole
or posaconazole. There is no mention of isavuconazole in the
guidelines due to lack of data. There has only been one significant
human randomized, double blind, multicenter, non-inferiority
candidemia study, which evaluated the role of initial isavuconazole
versus caspofungin. Patients were assigned to either IV isavuco-
nazole followed by oral isavuconazole or IV caspofungin followed
by oral voriconazole as initial therapies for candidemia and other
invasive candidiasis. There were total of 67 patients with invasive
candidiasis (29 in the isavuconazole arm and 38 in the caspofungin
arms) with response rates of 34.5 % for isavuconazole and 65.8 % for
caspofungin. Isavuconazole was favored as the oral step-down
therapy when compared to voriconazole. While the failure of
voriconazole was 15 %, it was reported at only 5.8 % for
isavuconazole. Given the performance of oral isavuconazole as a
step-down therapy in this study, it is potentially a reasonable
treatment option for fluconazole-resistant isolates [20].
In our case, fluconazole, voriconazole and posaconazole showed
resistance to C. tropicalis so we chose isavuconazole based on the
susceptibilities. There is no human data suggesting that in-vitro
resistance lead to poor clinical outcomes. In a Taiwanese study,
Chen et al. showed 16.9 % patients infected with fluconazole non-
susceptible C. tropicalis had cross-resistance to itraconazole,
voriconazole, and posaconazole even though 55.2 % of patients
were azole naïve [21]. In an in-vitro study, Paul et al. found that 4
out of 9 fluconazole induced resistant isolates with MICs  128
mg/l also developed cross-resistance to other azoles including
posaconazole, voriconazole and itraconazole but the resistance
was not long lasting. Isavuconazole was not tested in this study
[22].
Our case adds to the growing evidence that right-sided Candida
endocarditis patients who are not surgical candidates can be
managed successfully with an AngioVac procedure. The patient
was treated with intravenous echinocandin for six weeks as he had
idiosyncratic reaction to amphotericin B. For long-term suppres-
sion, fluconazole is the most commonly used azole and alternatives
are voriconazole and posaconazole. The patient was suppressed
with isavuconazole due to resistance to other azoles. It shows the
importance of requesting susceptibilities to all azoles. We need
more studies, which include isavuconazole, to understand the
correlation between in-vitro azole resistance to C tropicalis and its
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